169 related articles for article (PubMed ID: 21386785)
1. The use of dosimetry in the treatment of differentiated thyroid cancer.
Lassmann M; Hänscheid H; Verburg FA; Luster M
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):107-15. PubMed ID: 21386785
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry and thyroid cancer: the individual dosage of radioiodine.
Lassmann M; Reiners C; Luster M
Endocr Relat Cancer; 2010 Sep; 17(3):R161-72. PubMed ID: 20448022
[TBL] [Abstract][Full Text] [Related]
3. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C
Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649
[TBL] [Abstract][Full Text] [Related]
4. Individualized dosimetry in the management of metastatic differentiated thyroid cancer.
Chiesa C; Castellani MR; Vellani C; Orunesu E; Negri A; Azzeroni R; Botta F; Maccauro M; Aliberti G; Seregni E; Lassmann M; Bombardieri E
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):546-61. PubMed ID: 19910908
[TBL] [Abstract][Full Text] [Related]
5. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
7. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
8. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
9. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
10. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
11. A dosimetric algorithm for patient-specific 131I therapy of thyroid cancer based on a prescribed target-mass reduction.
Traino AC; Di Martino F
Phys Med Biol; 2006 Dec; 51(24):6449-56. PubMed ID: 17148828
[TBL] [Abstract][Full Text] [Related]
12. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine ablation: when and how.
Ambrosetti MC; Colato C; Dardano A; Monzani F; Ferdeghini M
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):473-81. PubMed ID: 19910900
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine ablation for differentiated thyroid cancer-none, one dose or two?
Rees GJ
Clin Oncol (R Coll Radiol); 2010 Mar; 22(2):131-5. PubMed ID: 19969444
[TBL] [Abstract][Full Text] [Related]
16. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
Freudenberg LS; Jentzen W; Görges R; Petrich T; Marlowe RJ; Knust J; Bockisch A
Nuklearmedizin; 2007; 46(4):121-8. PubMed ID: 17690789
[TBL] [Abstract][Full Text] [Related]
17. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].
Dietlein M; Dressler J; Eschner W; Grünwald F; Lassmann M; Leisner B; Luster M; Moser E; Reiners C; Schicha H; Schober O; ;
Nuklearmedizin; 2007; 46(5):213-9. PubMed ID: 17938757
[TBL] [Abstract][Full Text] [Related]
18. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS).
Schuck A; Biermann M; Pixberg MK; Müller SB; Heinecke A; Schober O; Willich N
Strahlenther Onkol; 2003 Dec; 179(12):832-9. PubMed ID: 14652672
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients.
Maxon HR; Englaro EE; Thomas SR; Hertzberg VS; Hinnefeld JD; Chen LS; Smith H; Cummings D; Aden MD
J Nucl Med; 1992 Jun; 33(6):1132-6. PubMed ID: 1597728
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine therapy in differentiated thyroid carcinoma.
Salvatori M; Rufini V; Garganese MC; Di Giuda D
Rays; 2000; 25(2):221-38. PubMed ID: 11370540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]